Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

A Randomized, Placebo-Controlled, Double-Blind, Dose Escalation, Single Dose and Steady State Pharmacokinetics Study of 9cUAB30 in Healthy Volunteers.

Kolesar JM, Andrews S, Green H, Havighurst TC, Wollmer BW, DeShong K, Laux DE, Krontiras H, Muccio DD, Kim K, Grubbs CJ, House MG, Parnes HL, Heckman-Stoddard BM, Bailey HH.

Cancer Prev Res (Phila). 2019 Sep 4. pii: canprevres.0310.2019. doi: 10.1158/1940-6207.CAPR-19-0310. [Epub ahead of print]

PMID:
31484659
2.

Defective DNA repair in hereditary ovarian cancers: Implications for therapy.

Burgess BT, Kolesar JM.

Am J Health Syst Pharm. 2018 Nov 1;75(21):1697-1707. doi: 10.2146/ajhp180124. Epub 2018 Sep 18. Review.

PMID:
30228165
3.

Reply to I.F. Tannock, P. Isaacsson Velho et al, R.Z. Szmulewitz et al, M. Tiako Meyo et al, and F.J.S.H. Woei-A-Jin et al.

Kolesar JM, Liu G.

J Clin Oncol. 2018 Oct 20;36(30):3065-3066. doi: 10.1200/JCO.2018.79.3208. Epub 2018 Sep 6. No abstract available. Erratum in: J Clin Oncol. 2018 Dec 1;36(34):3436.

PMID:
30188791
4.

EML4-ALK rearrangement in squamous cell carcinoma shows significant response to anti-ALK inhibitor drugs crizotinib and alectinib.

Huang T, Engelmann BJ, Morgan RM, Absher KJ, Kolesar JM, Villano JL.

Cancer Chemother Pharmacol. 2018 May;81(5):965-968. doi: 10.1007/s00280-018-3571-2. Epub 2018 Apr 2.

PMID:
29610932
5.

Low-Fat Abiraterone Food Effect Is of Little Consequence.

Kolesar JM, Liu GX.

J Clin Oncol. 2018 May 10;36(14):1385-1386. doi: 10.1200/JCO.2018.78.0684. Epub 2018 Mar 28. No abstract available. Erratum in: J Clin Oncol. 2018 Dec 1;36(34):3436.

PMID:
29590006
6.

Smoking, Sex, and Non-Small Cell Lung Cancer: Steroid Hormone Receptors in Tumor Tissue (S0424).

Cheng TD, Darke AK, Redman MW, Zirpoli GR, Davis W, Payne Ondracek R, Bshara W, Omilian AR, Kratzke R, Reid ME, Molina JR, Kolesar JM, Chen Y, MacRae RM, Moon J, Mack P, Gandara DR, Kelly K, Santella RM, Albain KS, Ambrosone CB.

J Natl Cancer Inst. 2018 Jul 1;110(7):734-742. doi: 10.1093/jnci/djx260.

7.

A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors.

Becher OJ, Millard NE, Modak S, Kushner BH, Haque S, Spasojevic I, Trippett TM, Gilheeney SW, Khakoo Y, Lyden DC, De Braganca KC, Kolesar JM, Huse JT, Kramer K, Cheung NV, Dunkel IJ.

PLoS One. 2017 Jun 5;12(6):e0178593. doi: 10.1371/journal.pone.0178593. eCollection 2017.

8.

Thiazolothiazole Fluorophores Exhibiting Strong Fluorescence and Viologen-Like Reversible Electrochromism.

Woodward AN, Kolesar JM, Hall SR, Saleh NA, Jones DS, Walter MG.

J Am Chem Soc. 2017 Jun 28;139(25):8467-8473. doi: 10.1021/jacs.7b01005. Epub 2017 Jun 2.

PMID:
28481091
9.

Assessment of adherence and relative dose intensity with oral chemotherapy in oncology clinical trials at an academic medical center.

Engle JA, Traynor AM, Campbell TC, Wisinski KB, LoConte N, Liu G, Wilding G, Kolesar JM.

J Oncol Pharm Pract. 2018 Jul;24(5):348-353. doi: 10.1177/1078155217704989. Epub 2017 Apr 29.

10.

A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab.

Sawas A, Farber CM, Schreeder MT, Khalil MY, Mahadevan D, Deng C, Amengual JE, Nikolinakos PG, Kolesar JM, Kuhn JG, Sportelli P, Miskin HP, O'Connor OA.

Br J Haematol. 2017 Apr;177(2):243-253. doi: 10.1111/bjh.14534. Epub 2017 Feb 21.

11.

A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors.

Becher OJ, Gilheeney SW, Khakoo Y, Lyden DC, Haque S, De Braganca KC, Kolesar JM, Huse JT, Modak S, Wexler LH, Kramer K, Spasojevic I, Dunkel IJ.

Pediatr Blood Cancer. 2017 Jul;64(7). doi: 10.1002/pbc.26409. Epub 2016 Dec 30.

PMID:
28035748
12.

A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors.

Kyriakopoulos CE, Braden AM, Kolesar JM, Eickhoff JC, Bailey HH, Heideman J, Liu G, Wisinski KB.

Invest New Drugs. 2017 Jun;35(3):290-297. doi: 10.1007/s10637-016-0418-8. Epub 2016 Dec 21.

13.

Prioritization of family member sequencing for the detection of rare variants.

Sippy R, Kolesar JM, Darst BF, Engelman CD.

BMC Proc. 2016 Oct 18;10(Suppl 7):227-231. eCollection 2016.

14.

Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer.

Wisinski KB, Tevaarwerk AJ, Burkard ME, Rampurwala M, Eickhoff J, Bell MC, Kolesar JM, Flynn C, Liu G.

Clin Cancer Res. 2016 Jun 1;22(11):2659-67. doi: 10.1158/1078-0432.CCR-15-2365. Epub 2016 Mar 29.

15.

Pharmacokinetic/Toxicity Properties of the New Anti-Staphylococcal Lead Compound SK-03-92.

Schwan WR, Kolesar JM, Kabir MS, Elder EJ Jr, Williams JB, Minerath R, Cook JM, Witzigmann CM, Monte A, Flaherty T.

Antibiotics (Basel). 2015 Dec;4(4):617-626. Epub 2015 Nov 24.

16.

Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma.

Ivashko IN, Kolesar JM.

Am J Health Syst Pharm. 2016 Feb 15;73(4):193-201. doi: 10.2146/ajhp140768. Review.

PMID:
26843495
17.

Treatment of chronic myelogenous leukemia.

Kujak C, Kolesar JM.

Am J Health Syst Pharm. 2016 Feb 1;73(3):113-20. doi: 10.2146/ajhp140686. Review.

PMID:
26796903
18.

A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer.

Deming DA, Cavalcante LL, Lubner SJ, Mulkerin DL, LoConte NK, Eickhoff JC, Kolesar JM, Fioravanti S, Greten TF, Compton K, Doyle AG, Wilding G, Duffy A, Liu G.

Invest New Drugs. 2016 Apr;34(2):168-75. doi: 10.1007/s10637-015-0314-7. Epub 2015 Dec 14.

19.

Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.

Croegaert K, Kolesar JM.

Am J Health Syst Pharm. 2015 Sep 1;72(17):1456-62. doi: 10.2146/ajhp140836. Review.

PMID:
26294238
20.

Pharmacodynamic study of axitinib in patients with advanced malignancies assessed with (18)F-3'deoxy-3'fluoro-L-thymidine positron emission tomography/computed tomography.

Bruce JY, Scully PC, Carmichael LL, Eickhoff JC, Perlman SB, Kolesar JM, Heideman JL, Jeraj R, Liu G.

Cancer Chemother Pharmacol. 2015 Jul;76(1):187-95. doi: 10.1007/s00280-015-2779-7. Epub 2015 May 29.

21.

Potential cytochrome P-450 drug-drug interactions in adults with metastatic solid tumors and effect on eligibility for Phase I clinical trials.

Wisinski KB, Cantu CA, Eickhoff J, Osterby K, Tevaarwerk AJ, Heideman J, Liu G, Wilding G, Johnston S, Kolesar JM.

Am J Health Syst Pharm. 2015 Jun 1;72(11):958-65. doi: 10.2146/ajhp140591.

22.

Importance of ethnicity and smoking status in EGFR gene testing in lung cancers.

Engle JA, Kolesar JM.

Am J Health Syst Pharm. 2015 May 1;72(9):686-7. doi: 10.2146/ajhp150001. No abstract available.

PMID:
25873612
23.

Opportunities for drug repositioning from phenome-wide association studies.

Rastegar-Mojarad M, Ye Z, Kolesar JM, Hebbring SJ, Lin SM.

Nat Biotechnol. 2015 Apr;33(4):342-5. doi: 10.1038/nbt.3183. No abstract available.

PMID:
25850054
25.

Assessment of adherence with oral anticancer agents in oncology clinical trials: A systematic review.

Bergsbaken JJ, Eickhoff JC, Buss BA, Mably MS, Kolesar JM.

J Oncol Pharm Pract. 2016 Feb;22(1):105-13. doi: 10.1177/1078155214567163. Epub 2015 Jan 10.

PMID:
25577495
26.

Afatinib: A first-line treatment for selected patients with metastatic non-small-cell lung cancer.

Engle JA, Kolesar JM.

Am J Health Syst Pharm. 2014 Nov 15;71(22):1933-8. doi: 10.2146/ajhp130654. Review.

PMID:
25349236
27.

Glucarpidase for the management of elevated methotrexate levels in patients with impaired renal function.

Fermiano M, Bergsbaken J, Kolesar JM.

Am J Health Syst Pharm. 2014 May 15;71(10):793-8. doi: 10.2146/ajhp130483. Review.

PMID:
24780487
28.

Soy food frequency questionnaire does not correlate with baseline isoflavone levels in patients with bladder cancer.

Kolesar JM, Pomplun M, Havighurst T, Stublaski J, Wollmer B, Kim K, Tangrea JA, Parnes HL, House MG, Gee J, Messing E, Bailey HH.

J Oncol Pharm Pract. 2015 Apr;21(2):128-31. doi: 10.1177/1078155214528552. Epub 2014 Mar 17.

29.

Serotonin type 3-receptor antagonists for chemotherapy-induced nausea and vomiting: therapeutically equivalent or meaningfully different?

Kolesar JM, Eickhoff J, Vermeulen LC.

Am J Health Syst Pharm. 2014 Mar 15;71(6):507-10. doi: 10.2146/ajhp130653. Review. No abstract available.

30.

A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignancies.

Bruce JY, Kolesar JM, Hammers H, Stein MN, Carmichael L, Eickhoff J, Johnston SA, Binger KA, Heideman JL, Perlman SB, Jeraj R, Liu G.

Cancer Chemother Pharmacol. 2014 Mar;73(3):485-93. doi: 10.1007/s00280-013-2373-9. Epub 2014 Jan 12.

31.

Prevention and treatment of chemotherapy-induced peripheral neuropathy.

Piccolo J, Kolesar JM.

Am J Health Syst Pharm. 2014 Jan 1;71(1):19-25. doi: 10.2146/ajhp130126. Review.

PMID:
24352178
32.

Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503).

Brahmer JR, Lee JW, Traynor AM, Hidalgo MM, Kolesar JM, Siegfried JM, Guaglianone PP, Patel JD, Keppen MD, Schiller JH.

Eur J Cancer. 2014 Jan;50(2):302-8. doi: 10.1016/j.ejca.2013.10.006. Epub 2013 Nov 15.

33.

A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors.

Deming DA, Ninan J, Bailey HH, Kolesar JM, Eickhoff J, Reid JM, Ames MM, McGovern RM, Alberti D, Marnocha R, Espinoza-Delgado I, Wright J, Wilding G, Schelman WR.

Invest New Drugs. 2014 Apr;32(2):323-9. doi: 10.1007/s10637-013-0035-8. Epub 2013 Oct 10.

34.

A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies.

Schelman WR, Traynor AM, Holen KD, Kolesar JM, Attia S, Hoang T, Eickhoff J, Jiang Z, Alberti D, Marnocha R, Reid JM, Ames MM, McGovern RM, Espinoza-Delgado I, Wright JJ, Wilding G, Bailey HH.

Invest New Drugs. 2013 Dec;31(6):1539-46. doi: 10.1007/s10637-013-0029-6. Epub 2013 Oct 10.

35.

Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genes.

Kolesar JM, Traynor AM, Holen KD, Hoang T, Seo S, Kim K, Alberti D, Espinoza-Delgado I, Wright JJ, Wilding G, Bailey HH, Schelman WR.

Cancer Chemother Pharmacol. 2013 Sep;72(3):661-7. doi: 10.1007/s00280-013-2242-6. Epub 2013 Aug 1.

36.

A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer.

Schelman WR, Mohammed TA, Traynor AM, Kolesar JM, Marnocha RM, Eickhoff J, Keppen M, Alberti DB, Wilding G, Takebe N, Liu G.

Invest New Drugs. 2014 Apr;32(2):295-302. doi: 10.1007/s10637-013-9999-7. Epub 2013 Jul 17.

37.

Vemurafenib and ipilimumab: new agents for metastatic melanoma.

Banaszynski M, Kolesar JM.

Am J Health Syst Pharm. 2013 Jul 15;70(14):1205-10. doi: 10.2146/ajhp120260. Review.

PMID:
23820456
38.

Assays for biological agents.

Kolesar JM, Vermeulen L.

Am J Health Syst Pharm. 2013 Jul 1;70(13):1101. doi: 10.2146/ajhp130128. No abstract available.

PMID:
23784155
39.

Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study.

Hoang T, Campbell TC, Zhang C, Kim K, Kolesar JM, Oettel KR, Blank JH, Robinson EG, Ahuja HG, Kirschling RJ, Johnson PH, Huie MS, Wims ME, Larson MM, Hernan HR, Traynor AM.

Invest New Drugs. 2014 Feb;32(1):195-9. doi: 10.1007/s10637-013-9980-5. Epub 2013 Jun 1.

40.

Vismodegib for the treatment of basal cell skin cancer.

Poggi L, Kolesar JM.

Am J Health Syst Pharm. 2013 Jun 15;70(12):1033-8. doi: 10.2146/ajhp120311. Review.

PMID:
23719880
41.

Crizotinib for the treatment of non-small-cell lung cancer.

Timm A, Kolesar JM.

Am J Health Syst Pharm. 2013 Jun 1;70(11):943-7. doi: 10.2146/ajhp120261.

PMID:
23686600
42.

Vandetanib: a novel targeted therapy for the treatment of metastatic or locally advanced medullary thyroid cancer.

Ton GN, Banaszynski ME, Kolesar JM.

Am J Health Syst Pharm. 2013 May 15;70(10):849-55. doi: 10.2146/ajhp120253. Review.

PMID:
23640345
43.

Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial.

Argiris A, Ghebremichael M, Gilbert J, Lee JW, Sachidanandam K, Kolesar JM, Burtness B, Forastiere AA.

J Clin Oncol. 2013 Apr 10;31(11):1405-14. doi: 10.1200/JCO.2012.45.4272. Epub 2013 Mar 4.

44.

Stability of stock and diluted rituximab.

Zhang Y, Vermeulen LC, Kolesar JM.

Am J Health Syst Pharm. 2013 Mar 1;70(5):436-8. doi: 10.2146/ajhp120035.

45.

Unexpected doxorubicin-mediated cardiotoxicity in sisters: possible role of polymorphisms in histamine n-methyl transferase.

Sachidanandam K, Gayle AA, Robins HI, Kolesar JM.

J Oncol Pharm Pract. 2013 Sep;19(3):269-72. doi: 10.1177/1078155212461022. Epub 2012 Nov 15.

46.

Stability of infliximab in polyvinyl chloride bags.

Ikeda R, Vermeulen LC, Lau E, Jiang Z, Saha S, Reichelderfer M, Kolesar JM.

Am J Health Syst Pharm. 2012 Sep 1;69(17):1509-12. doi: 10.2146/ajhp100116.

47.

Exemestane for primary prevention of breast cancer in postmenopausal women.

Zhang Y, Simondsen K, Kolesar JM.

Am J Health Syst Pharm. 2012 Aug 15;69(16):1384-8. doi: 10.2146/ajhp110585.

PMID:
22855103
48.

Pharmacokinetic study of 3-in-1 poly(ethylene glycol)-block-poly(D, L-lactic acid) micelles carrying paclitaxel, 17-allylamino-17-demethoxygeldanamycin, and rapamycin.

Shin HC, Cho H, Lai TC, Kozak KR, Kolesar JM, Kwon GS.

J Control Release. 2012 Oct 10;163(1):93-9. doi: 10.1016/j.jconrel.2012.04.024. Epub 2012 Apr 23.

49.

Lenalidomide-induced elevated bilirubin.

Simondsen KA, Kolesar JM.

J Oncol Pharm Pract. 2012 Dec;18(4):402-5. doi: 10.1177/1078155212439492. Epub 2012 Mar 9.

PMID:
22407059
50.

Eltrombopag: an oral thrombopoietin receptor agonist for the treatment of idiopathic thrombocytopenic purpura.

Zhang Y, Kolesar JM.

Clin Ther. 2011 Nov;33(11):1560-76. doi: 10.1016/j.clinthera.2011.10.004. Epub 2011 Nov 4. Review.

PMID:
22054810

Supplemental Content

Loading ...
Support Center